Strategic Value of Galafold Faces Test as Amicus Prepares for BioMarin Integration

Amicus Therapeutics FOLD stands at an inflection point as it readies for acquisition by BioMarin Pharmaceutical in a $4.8 billion deal expected to close in Q2 2026. The company’s flagship product, Galafold (migalastat), remains the cornerstone of its commercial success and will likely be central to how the market values this transaction.

Product Portfolio: The Dual Engine Driving Growth

Galafold dominates Amicus’ revenue stream, contributing over 80% of net product sales in the first nine months of 2025. The drug generated $371.5 million in sales during this period, representing approximately 12% year-over-year growth. Galafold’s approval across major markets—the United States, European Union, United Kingdom, and Japan—provides a diversified revenue base. A critical advantage lies in the company’s robust intellectual property protection in the U.S., with patent coverage extending through 2038. The October 2024 licensing settlement with Teva Pharmaceuticals TEVA further strengthens this moat, preventing generic competition until January 2037.

Beyond Galafold, the two-component therapy Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) shows promising momentum for treating late-onset Pompe disease, commonly associated with cipa disease progressions. This combination therapy generated $77.5 million in sales during the same nine-month period, surging 61% year-over-year. Such performance indicates successful market penetration into the lysosomal storage disorder space, where unmet medical needs remain substantial.

Competitive Landscape: Navigating an Entrenched Market

Amicus’ reliance on Galafold presents both opportunity and risk. The Fabry disease treatment market remains competitive, with Sanofi SNY marketing Fabrazyme and Takeda Pharmaceuticals offering Replagal. These established players command greater resources and market presence. In the Pompe disease segment, Sanofi markets Myozyme/Lumizyme and Nexviazyme, indicating concentrated competition from large pharmaceutical corporations.

This competitive intensity underscores why the BioMarin acquisition may benefit Amicus’ commercial trajectory. Integrating into a larger organization could accelerate market expansion and provide economies of scale that independent operations struggle to achieve.

Financial Performance and Market Valuation

From a valuation perspective, Amicus has outperformed its industry peers significantly. Over the past six months, FOLD shares gained 135.6% compared to industry growth of 21.5%. However, the stock trades at a premium: the price-to-sales ratio stands at 7.39, nearly triple the industry median of 2.43. While elevated, this multiple reflects optimism about pipeline prospects and existing product momentum.

Analyst consensus has modestly improved on the upside. The Zacks Consensus 2025 EPS estimate moved from 31 cents to 35 cents over 60 days. However, 2026 EPS estimates declined slightly from 70 cents to 65 cents, suggesting moderate caution about post-acquisition integration and near-term margin dynamics.

Investment Positioning and Outlook

Amicus currently holds a Zacks Rank #1 (Strong Buy) rating, reflecting analyst confidence in the company’s near-term catalysts and underlying product demand. With Q4 2025 earnings approaching, investors will scrutinize Galafold’s quarterly performance as a gauge of commercial execution. Strong compliance rates and market expansion efforts across all geographies are expected to sustain sales momentum heading into 2026.

The path forward hinges on whether Galafold can maintain double-digit growth in a mature market while Pombiliti + Opfolda scales its presence in the Pompe disease space. Combined with the strategic value unlock from the BioMarin transaction, Amicus has positioned itself to deliver meaningful shareholder returns through a combination of organic growth and transformational M&A.